EB,TH,CS,PZAを使用した再治療成績第9次国療化研B研究報告(第1部)
1968 年 43 巻 2 号 p. 91-95
詳細
1968 年 43 巻 2 号 p. 91-95
Retreatment cases who had not been treated previously by at least any two drugs amongethionamide (T), cycloserine (C), and pyrazinamide (P) were accepted to the trial and they were allocated to the following four regimens so as to have a combination of ethambutol (E)and two unused drugs.
(1) T 0.5 g daily + E 0.5 g daily H-E 1.0 g daily
(2) C 0.5 g daily + E 1.0 g daily P 1.5 g daily
(3) T 0.5 daily + E 1.0 g daily + P 1.5 g daily (4) T 0.5 g daily + C 0.5 g daily + P 1.5 g daily + E 1.0 g daily After the exclusion of ineligible cases, there remained 6 0 cases in (1), 63 cases in (2), 58cases in (3) and 51 cases in (4), but as for the evaluation of clinical efficacy, only the subjects who had been treated by the allocated regimen for more than 3 months were analysed: 40 cases in (1), 52 cases in (2), 42 cases in (3) and 33 cases in (4). The number of excluded cases at the start of trial and the number of withdrawn cases during the trial are indicated in Tables 1 and 2. Comparability among the four treatment groups are shown in Figs.1 and 2. The rate of culture conversion is higher in the regimens which contain both E and T (regimen (1) and (3)) than the regimen which contains only E (regimen (2)) in the case of triple drug combination and the four drug regimen (regimen (4)) is not advantageous over the three drug regimens (regimen (1) and (3)) as shown in Fig.3. It is noteworthy that about 90% of the failure cases in initial and re-treatment can be converted to negative by the simultaneous use of E and T. As for rad i o graphic response, the rate of regression is slight as shown in Figs.4, 5 and 6, for almost all subjects had very long history of chemotherapy. The order of improvement is different from the rate of sputum conversion and the four drug regimen (4) stands the first in this respect.
